

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

Performance as at 31 May 2022¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) ²
Total Return	-0.14	0.31	5.14	10.39	8.89	8.00	6.26	10.64	6.94
Income ³	0.00	1.54	3.13	7.30	8.18	8.29	8.08	9.28	7.31
Growth	-0.14	-1.23	2.01	3.09	0.71	-0.29	-1.82	1.36	-0.37
Avg. Market Exposure ⁵	54%	54%	55%	57%	55%	58%	59%	59%	61%

² Inception date for performance calculation is 18 August 2008


- 3 Income includes realised capital gains 4 Past performance is not a reliable indicator of future performance
- 5 Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from September 2008

Growth of \$10,000 Since Inception⁶



⁶ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance

Annual Distributions⁷



7 Illustrates Distribution Returns for the Talaria Global Equity Fund (Managed Fund) Units for the financial year ending 30 June 2021. Inception date is 18 August 2008.



330 Collins Street Melbourne, VIC, Australia 3000 info@talariacapital.com.au talariacapital.com.au




Top 10 Holdings⁸

Company Name	Holding	Country	Sector	Description
Johnson & Johnson	5.2%	USA	Healthcare	Pharmaceutical, medical devices and consumer health products company
Sanofi	5.0%	France	Healthcare	Top 5 pharmaceutical firm with leading positions in diabetes and rare diseases
Alibaba	5.0%	Hong Kong	Consumer Discretionary	One of the world's largest eCommerce and technology groups
Secom	4.9%	Japan	Industrials	Japan's largest protective and electronic security solutions provider
Sodexo	4.4%	France	Consumer Discretionary	A multinational food services and facilities management company
Everest Re	4.3%	USA	Financials	Leading global provider of reinsurance and insurance services
Roche	4.3%	Switzerland	Healthcare	A global leader in Cancer treatments
Gilead	4.2%	USA	Healthcare	Leading research based biopharmaceutical company
Mitsubishi Electric	3.8%	Japan	Industrials	One of Japan's largest industrial conglomerates
Femsa	3.8%	Mexico	Consumer Staples	Operates largest Mexican convenience store chain, and part owner of Coca-Cola bottling and Heineken


⁸ Weightings include option positions held and cash backing put options. It assumes that put options will be exercised.

Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation9



Regional Allocation¹⁰



^{9,10} Weightings include option positions held and cash backing put options It assumes that put options will be exercised.

Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options

Fund Snapshot

AUS0035AU	Inception Date	18 August 2008	
1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily	
Estimated to be 0.12% of net asset value	Exit Price	\$4.7499 (31 May 2022)	
of the Fund each Financial Year	Buy / Sell Spread	0.20% / 0.20%	
AMP North, Asgard, Ausmaq,	Distributions	Quarterly	
FirstChoice, Escala, Evans & Partners, Freedom of Choice, Hub24, IOOF, Linear, Macquarie, Morgan Stanley, Netwealth, Powerwrap, Praemium, Xplore Wealth	Minimum Investment	\$5,000	
	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses Estimated to be 0.12% of net asset value of the Fund each Financial Year AMP North, Asgard, Ausmaq, BT Wrap/Panorama, CFS Firstwrap, CFS FirstChoice, Escala, Evans & Partners, Freedom of Choice, Hub24, IOOF, Linear, Macquarie, Morgan Stanley, Netwealth,	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses Estimated to be 0.12% of net asset value of the Fund each Financial Year Exit Price Buy / Sell Spread AMP North, Asgard, Ausmaq, BT Wrap/Panorama, CFS Firstwrap, CFS FirstChoice, Escala, Evans & Partners, Freedom of Choice, Hub24, IOOF, Linear, Macquarie, Morgan Stanley, Netwealth, Minimum Investment	

Important Information

